Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Stirling John Edwards"'
ISCOMATRIX™ adjuvant reduces mucosal tolerance for effective pulmonary vaccination against influenza
Autor:
Jean-Pierre Y. Scheerlinck, Ana Tokanovic, Stirling John Edwards, Kenneth J. Snibson, Philip Sutton, Martin J. Pearse, Andrea A Timothy
Publikováno v:
Human Vaccines & Immunotherapeutics. 11:377-385
While most pathogens infect via mucosal surfaces, most current vaccines are delivered by injection. This situation remains despite awareness of the potential benefits of mucosal delivery for inducing protection against mucosa-infecting pathogens. A m
Autor:
Janet L. Wee, Stirling John Edwards, Martin J. Pearse, Kenneth J. Snibson, Jean-Pierre Y. Scheerlinck, Philip Sutton, Ana Vujanic
Publikováno v:
Clinical and Vaccine Immunology. 19:79-83
Pulmonary delivery of an influenza Iscomatrix adjuvant vaccine induces a strong systemic and mucosal antibody response. Since an influenza vaccine needs to induce immunological memory that lasts at least 1 year for utility in humans, we examined the
Autor:
Caroline D Skene, Philip Sutton, Stirling John Edwards, Alison L. Every, Margaret Bridget Holland Moloney, Garrett Z. Ng, Andrew Stent
Publikováno v:
Vaccine. 29:1514-1518
Helicobacter pylori, the major cause of gastric cancer, have mechanisms that allow colonization of the inhospitable gastric mucosa, including enzymes such as superoxide dismutase (SOD) which protect against reactive oxygen species. As SOD is essentia
Autor:
Martin J. Pearse, Kenneth J. Snibson, Stirling John Edwards, Jean-Pierre Y. Scheerlinck, Charles Quinn, Philip Sutton, Janet L. Wee
Publikováno v:
Mucosal Immunology. 1:489-496
Using a large animal model, we evaluated whether delivery of influenza vaccine via its mucosal site of infection could improve vaccine effectiveness. Unexpectedly, pulmonary immunization with extremely low antigen doses (0.04 microg influenza) induce
Autor:
Stirling John Edwards, Fasséli Coulibaly, Heidi E. Drummer, Yousef M O Alhammad, Patricia Vietheer, Kathleen McCaffrey, Charles Quinn, David N Harrison, Pantelis Poumbourios, Jun Gu, S F Irene Boo
Publikováno v:
Journal of Virology
Hepatitis C virus (HCV) envelope glycoproteins E1 and E2 form a heterodimer and mediate receptor interactions and viral fusion. Both E1 and E2 are targets of the neutralizing antibody (NAb) response and are candidates for the production of vaccines t
Autor:
Alan Coulter, Stirling John Edwards, Phil Sutton, Martin J. Pearse, Susie Gekas, Hung-Hsun Yen, Jean-Pierre Y. Scheerlinck
Publikováno v:
Vaccine. 24:3929-3936
A key barrier to producing effective nasal immunisations is the low efficiency of uptake of vaccines across the nasal mucosa. Using a recently developed cannulation system, we examined the antibody response induced by nasal immunisation with an ISCOM
Autor:
Yok Teng Chionh, Garrett Z. Ng, Lynette S R Ong, Stirling John Edwards, Philip Sutton, Andrew Stent, Alison L. Every
Publikováno v:
Vaccine. 30(50)
Helicobacter pylori is an important pathogen of the human stomach, and the development of a protective vaccine has been an enticing goal for many years. The H. pylori antioxidant enzymes superoxide dismutase (SOD) and catalase (KatA) have been shown
Publikováno v:
Biochemical and Biophysical Research Communications. 190:536-543
Factor VIII is a complex, plasma glycoprotein involved in the process of blood coagulation. Production of the recombinant molecule has largely been confined to mammalian cell systems which have, in general, proven to be inefficient producers of facto
Autor:
Ana Vujanic, Jean-Pierre Y. Scheerlinck, Kenneth J. Snibson, Margaret Bridget Holland Moloney, Stirling John Edwards, Philip Sutton, Charles Quinn, Martin J. Pearse, Janet L. Wee, Shirley Taylor
Publikováno v:
Vaccine. 28(14)
Deep pulmonary delivery of an influenza ISCOMATRIX™ vaccine has previously been shown to induce a combined mucosal and systemic antibody response. To explore whether this combined response is influenced by intrinsic properties of the component anti
Publikováno v:
Helicobacter. 13(6)
Background: Adjuvant-free vaccines have many benefits, including decreased cost and toxicity. We examined the protective effect of systemic vaccination with adjuvant-free formalin-fixed Helicobacter pylori or bacterial lysate and the ability of this